| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,880 | 11,900 | 12:39 | |
| 11,825 | 11,970 | 13.03. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 12,650 | 699 | |||
| 12,645 | 699 | |||
| 12,465 | 37 | |||
| 12,455 | 37 | |||
| 12,445 | 74 | |||
| 12,075 | 699 | |||
| 12,065 | 699 | |||
| 12,055 | 1.193 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/via.htm [/URL] | ||||
| 494 | 12,000 | |||
| 74 | 11,615 | |||
| 37 | 11,605 | |||
| 37 | 11,595 | |||
| 699 | 11,385 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.341 | 3,085 | 4.137 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 13.03.2026 | 17:30:19 | 12,030 | 7 |
| 13.03.2026 | 16:47:01 | 12,035 | 128 |
| 13.03.2026 | 14:37:19 | 12,075 | 144 |
| Tagesumsatz Xetra | +0,085 +0,71 % | 1.712 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Viatris resolves case over use of woman's cancer cells to advance drug research | 8 | Seeking Alpha | ||
| VIATRIS Aktie jetzt für 0€ handeln | |||||
| Mi | GoodRx to offer up to 85% discount on Viatris drugs | 6 | Seeking Alpha | ||
| Mo | Dividendenbekanntmachungen (09.03.2026) | 7.102 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANSIX INC US00773T1016 0,16 USD 0,1377 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,29 USD 0,2496 EUR ALPHABET INC CDR CA02080K1049 0... ► Artikel lesen | |
| 01.03. | Notable healthcare headlines for the week: Viatris, Novo Nordisk, and Gilead Sciences in focus | 59 | Seeking Alpha | ||
| 27.02. | UBS raises Viatris stock price target to $20 on cost savings | 21 | Investing.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Fr | EQT exits Galderma Group AG in full via largest sponsor-backed block trade ever | PR Newswire | EQT completes final sell-down in Galderma, a global dermatology company delivering science-backed solutions to healthcare professionals, consumers and patients worldwideUnder EQT's ownership... ► Artikel lesen | |
| Fr | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | AFX News | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| Do | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | GlobeNewswire (Europe) | TONMYA (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA... ► Artikel lesen | |
| Do | TerrAscend Reports Fourth Quarter and Full Year 2025 Financial Results | GlobeNewswire (Europe) | Net Revenue of $66.1 million for Q4 2025 and $260.6 Million for FY 2025 Gross Profit Margin of 52.1% for Q4 2025 and 52.3% for FY 2025 from continuing operations Q4 2025 Net Cash provided from continuing... ► Artikel lesen | |
| Fr | Im Windschatten von Novo Nordisk: Dänisches Pharma-IPO voraus? | Der Aktionär | Dänemark und Pharma? In diesem Zusammenhang führt kein Weg an Novo Nordisk vorbei. Das Unternehmen, dessen Wurzeln bis ins Jahr 1923 reichen, war einst das wertvollste börsennotierte Unternehmen Europas.... ► Artikel lesen |